Copertina

Barriers to Medical Care Are Frequently Reported by Patients With Cirrhosis

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	William Chai, Nicole E. Rich, Yan Liu, Juana Campos, Lisa Quirk, Jennifer R. Kramer, Jahna Anyanwu, Amanda Gibbons, Aaron Loewy, Dalal Youssef, Riya Malhorta, Hadley McGhee, Meena Tadros, Fasiha Kanwal, Amit G. Singal
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alimentary Pharmacology & Therapeutics
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Editorial: Redefining Decompensation in Cirrhosis—More Than an Academic Playground? Authors' Reply
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Research Communication: Serum Metabolomic Signatures Predict Tumour Recurrence After Resection or Ablation in Patients With Early‐Stage Hepatocellular Carcinoma
di: Ashwini Arvind, et al.
Pubblicazione: (2025)

Very Early‐Stage Detection Is Associated With Improved Survival in Patients With Unifocal Hepatocellular Carcinoma
di: Thomas Hunold, et al.
Pubblicazione: (2025)

Refining Prognosis in Cirrhosis Patients With Ascites: Impact of Acute vs. Non‐Acute Decompensation
di: Lucie Simonis, et al.
Pubblicazione: (2025)

Editorial: Timely Follow‐Up in Cirrhosis: How Does It Work?
di: Nina Kimer, et al.
Pubblicazione: (2024)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation
di: Thanawin Pramotedham, et al.
Pubblicazione: (2026)

Letter: The Unresolved Issue of NSBB Confounding in Statin Research for Cirrhosis
di: Deliang Huang, et al.
Pubblicazione: (2026)

Psychiatric disorders in patients with hepatocellular carcinoma: A large US cohort of commercially insured individuals
di: Mausam J. Patel, et al.
Pubblicazione: (2024)

Disparities in Alcohol‐Associated Liver Disease Hospital Encounters Amongst a Texas‐Based Cohort of Patients
di: Thomas G. Cotter, et al.
Pubblicazione: (2025)

Editorial: Statin Therapy in Cirrhosis: More Than Just Lipid‐Lowering
di: Emily Stephenson, et al.
Pubblicazione: (2026)

Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Editorial: Linking Patients With Cirrhosis to Clinical Care—The Hurdles and Way Forward
di: Jimmy Che‐To Lai, et al.
Pubblicazione: (2026)

Unstable Recompensation: An Intermediate Subtype in Patients With HBV ‐Related Decompensated Cirrhosis
di: Shuai Xia, et al.
Pubblicazione: (2025)

Letter: Timely Follow‐Up in Cirrhosis—A Key Public Health Intervention
di: Mo‐Yao Tan, et al.
Pubblicazione: (2024)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
di: Mary Yue Wang, et al.
Pubblicazione: (2025)

Editorial: Diabetes Management in Cirrhosis—The Window of Opportunity Before Decompensation. Authors' Reply
di: Mary Yue Wang, et al.
Pubblicazione: (2026)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
di: Yu Shi, et al.
Pubblicazione: (2025)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
di: Zhanbo Qu
Pubblicazione: (2026)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
di: Eduardo Vilar‐Gomez, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
di: Sai Kiran Kuchana, et al.
Pubblicazione: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
di: Yuki Utakata, et al.
Pubblicazione: (2026)

Systematic Review: Imaging‐Based Morphological Criteria for Liver Cirrhosis—A Call to Standardise
di: Mei Chin Lim, et al.
Pubblicazione: (2026)

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis
di: Yee Hui Yeo, et al.
Pubblicazione: (2026)

Letter: Pharmacotherapy for Alcohol Dependence in Cirrhosis—By Addressing One Issue Do We Create Another?
di: Andrew W. Nguyen, et al.
Pubblicazione: (2026)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis
di: Stephanie Tsai, et al.
Pubblicazione: (2025)

Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease
di: Soroor Owrangi, et al.
Pubblicazione: (2024)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue?
di: Louise J. M. Alferink, et al.
Pubblicazione: (2024)

Letter: Statins for Cirrhosis: Are We Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management?
di: Abdulrahman Ismaiel
Pubblicazione: (2026)

Emerging Trends in Patients Hospitalised With Cirrhosis—Aetiologies, Complications and Outcomes Compared to Other Chronic Health Conditions
di: Julian Pohl, et al.
Pubblicazione: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
di: Christian Labenz, et al.
Pubblicazione: (2026)

Patient Plasma‐Induced Neutrophil Dysfunction Is Associated With Infection Risk and Mortality in Patients With Acute Decompensation of Cirrhosis
di: Supachaya Sriphoosanaphan, et al.
Pubblicazione: (2025)

Spontaneous Bacterial Peritonitis Is Associated With High Mortality, Which Interacts With Antibiotic Prophylaxis in a National Cirrhosis Cohort
di: Scott Silvey, et al.
Pubblicazione: (2025)

Correction to ‘Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct‐Acting Antivirals Versus Interferon’
Pubblicazione: (2025)

Editorial: Caught in the Middle—Exploring the Grey Zone Between Decompensated and Recompensated HBV ‐Related Cirrhosis. Authors' Reply
di: Bingqiong Wang, et al.
Pubblicazione: (2025)

Editorial: Navigating the Beta‐Blocker Dilemma in Advanced Liver Cirrhosis—When Is the Right Time to Discontinue? Authors' Reply
di: Ting Wang, et al.
Pubblicazione: (2024)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Editorial: Decoding Gut Failure in Cirrhosis—Villin‐1 and the Emergence of a Seventh Organ Failure. Authors' Reply
di: David Tornai, et al.
Pubblicazione: (2026)

Statin Therapy Independently Reduces Mortality and Liver Complications in Patients With Cirrhosis: An Updated Systematic Review and Meta‐Analysis
di: Bernardo de Faria Moraes, et al.
Pubblicazione: (2026)

Letter: Disease Stage and Absolute Risk in Evaluating the Branched‐Chain Amino Acid to Tyrosine Ratio in Cirrhosis. Authors' Reply
di: Takao Miwa, et al.
Pubblicazione: (2026)

Predicting Hepatic Decompensation in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease‐Related Cirrhosis: The ABID‐LSM Model
di: Luis Calzadilla Bertot, et al.
Pubblicazione: (2025)